Dallah Healthcare 9M 2022 net profit leaps 31% to SAR 196 mln; Q3 at SAR 43.9 mln

08/11/2022 Argaam Exclusive

View other reports

Dallah Healthcare Co. reported a net profit after Zakat and tax of SAR 196 million for the first nine months of 2022, leaping 31% from SAR 150 million in the same period last year.

Financials (M)

Item	9m 2021	9m 2022	Change‬
Revenues	1,529.61	1,794.11	17.3 %
Gross Income	537.46	655.29	21.9 %
Operating Income	211.43	290.80	37.5 %
Net Income	150.00	196.02	30.7 %
Average Shares	90.00	90.00	-
EPS (Riyals)	1.67	2.18	30.7 %

The improved results were due to the continued growth in operations, along with higher number of patients and occupancy rates in the inpatient and outpatient departments. The company also cited a decline in its share of losses from associates. However, it reported an increase in provisions for Zakat assessments for the previous years, as well as Murabaha financing cost.

The healthcare provider reported a net profit after Zakat and tax of SAR 43.9 million in Q3 2022, falling 12% year-on-year (YoY).

This was due to an increase in provisions for Zakat assessments for previous years, as well as Murabaha financing cost.

As compared to the previous quarter, net profit saw a drop of 36.9% from SAR 69.52 million.

Current Quarter Comparison (M)

Compared With The

Item	Q3 2021	Q3 2022	Change‬
Revenues	544.12	600.89	10.4 %
Gross Income	192.46	211.47	9.9 %
Operating Income	69.95	84.19	20.4 %
Net Income	49.85	43.87	(12.0 %)
Average Shares	90.00	90.00	-
EPS (Riyals)	0.55	0.49	(12.0 %)

Item	Q2 2022	Q3 2022	Change‬
Revenues	583.82	600.89	2.9 %
Gross Income	212.13	211.47	(0.3 %)
Operating Income	96.68	84.19	(12.9 %)
Net Income	69.52	43.87	(36.9 %)
Average Shares	90.00	90.00	-
EPS (Riyals)	0.77	0.49	(36.9 %)

Shareholders' equity, after deducting minority rights, amounted to SAR 1.976 billion at the end of the current period, compared to SAR 1.877 billion a year earlier.

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2013	183.73	19.3 %	84.40	15.9 %	38.39	1.0 %
Q2 2013	187.79	16.4 %	80.68	9.4 %	30.19	(20.9 %)
Q3 2013	167.08	17.4 %	66.67	13.0 %	21.95	(2.0 %)
Q4 2013	211.05	17.6 %	95.71	17.4 %	48.06	49.3 %
2013	749.65	17.7 %	327.45	14.1 %	137.53	5.2 %
Q1 2014	207.57	13.0 %	87.60	3.8 %	39.73	3.5 %
Q2 2014	219.45	16.9 %	93.78	16.2 %	33.46	10.8 %
Q3 2014	192.79	15.4 %	75.36	13.0 %	21.67	(1.3 %)
Q4 2014	240.08	13.8 %	103.54	8.2 %	50.24	4.5 %
2014	858.75	14.6 %	358.57	9.5 %	145.09	5.5 %
Q1 2015	240.40	15.8 %	102.13	16.6 %	39.67	(0.1 %)
Q2 2015	245.23	11.7 %	100.89	7.6 %	35.71	6.7 %
Q3 2015	223.93	16.2 %	87.92	16.7 %	26.37	21.7 %
Q4 2015	276.50	15.2 %	116.81	12.8 %	57.01	13.5 %
2015	985.44	14.8 %	407.14	13.5 %	160.78	10.8 %
Q1 2016	285.03	18.6 %	132.53	29.8 %	61.90	56.1 %
Q2 2016	288.35	17.6 %	129.78	28.6 %	59.34	66.2 %
Q3 2016	273.17	22.0 %	122.38	39.2 %	51.80	96.4 %
Q4 2016	316.24	14.4 %	151.01	29.3 %	57.96	1.7 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
Q1 2017	302.75	6.2 %	143.60	8.4 %	85.82	38.6 %
Q2 2017	288.20	0.0 %	130.48	0.5 %	70.86	19.4 %
Q3 2017	295.25	8.1 %	136.77	11.8 %	76.36	47.4 %
Q4 2017	325.87	3.0 %	148.23	(1.8 %)	74.95	29.3 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
Q1 2018	308.59	1.9 %	131.73	(8.3 %)	59.44	(30.7 %)
Q2 2018	273.13	(5.2 %)	92.38	(29.2 %)	19.67	(72.2 %)
Q3 2018	280.94	(4.8 %)	101.37	(25.9 %)	33.44	(56.2 %)
Q4 2018	318.28	(2.3 %)	110.86	(25.2 %)	33.04	(55.9 %)
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
Q1 2019	321.15	4.1 %	120.26	(8.7 %)	41.24	(30.6 %)
Q2 2019	286.00	4.7 %	92.46	0.1 %	18.06	(8.2 %)
Q3 2019	301.34	7.3 %	107.78	6.3 %	30.99	(7.3 %)
Q4 2019	343.60	8.0 %	127.34	14.9 %	64.09	94.0 %
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
Q1 2020	314.61	(2.0 %)	105.76	(12.1 %)	26.42	(35.9 %)
Q2 2020	247.56	(13.4 %)	67.77	(26.7 %)	7.97	(55.9 %)
Q3 2020	350.79	16.4 %	132.62	23.0 %	50.51	63.0 %
Q4 2020	405.30	18.0 %	143.57	12.7 %	40.26	(37.2 %)
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)
Q1 2021	494.67	57.2 %	176.82	67.2 %	72.91	176.0 %
Q2 2021	490.83	98.3 %	168.17	148.1 %	68.57	760.1 %
Q3 2021	544.12	55.1 %	192.46	45.1 %	69.95	38.5 %
Q4 2021	575.57	42.0 %	222.91	55.3 %	116.48	189.4 %
2021	2,105.18	59.7 %	760.36	69.1 %	327.92	162.0 %
Q1 2022	609.40	23.2 %	231.69	31.0 %	109.93	50.8 %
Q2 2022	583.82	18.9 %	212.13	26.1 %	96.68	41.0 %
Q3 2022	600.89	10.4 %	211.47	9.9 %	84.19	20.4 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2012	636.86	20.8 %	286.87	51.1 %	130.75	29.1 %
2013	749.65	17.7 %	327.45	14.1 %	137.53	5.2 %
2014	858.75	14.6 %	358.57	9.5 %	145.09	5.5 %
2015	985.44	14.8 %	407.14	13.5 %	160.78	10.8 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)
2021	2,105.18	59.7 %	760.36	69.1 %	327.92	162.0 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2013	39.04	2.8 %	0.43	-	39.04	0.43
Q2 2013	23.64	(36.3 %)	0.26	-	23.64	0.26
Q3 2013	21.84	(8.7 %)	0.24	-	21.84	0.24
Q4 2013	52.11	51.6 %	0.58	-	52.11	0.58
2013	136.63	2.5 %	1.52	-	136.63	1.52
Q1 2014	40.50	3.7 %	0.45	-	40.50	0.45
Q2 2014	34.33	45.2 %	0.38	-	34.33	0.38
Q3 2014	21.94	0.5 %	0.24	-	21.94	0.24
Q4 2014	50.35	(3.4 %)	0.56	-	50.35	0.56
2014	147.12	7.7 %	1.63	-	147.12	1.63
Q1 2015	47.82	18.1 %	0.53	13.75	34.07	0.38
Q2 2015	35.86	4.4 %	0.40	-	35.86	0.40
Q3 2015	26.78	22.1 %	0.30	-	26.78	0.30
Q4 2015	54.60	8.4 %	0.61	-	54.60	0.61
2015	165.06	12.2 %	1.83	13.75	151.31	1.68
Q1 2016	58.07	21.4 %	0.65	(2.02)	60.09	0.67
Q2 2016	54.14	51.0 %	0.60	(3.07)	57.21	0.64
Q3 2016	60.80	127.0 %	0.68	9.42	51.39	0.57
Q4 2016	51.71	(5.3 %)	0.57	(6.00)	57.71	0.64
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
Q1 2017	85.05	46.5 %	0.94	-	85.05	0.94
Q2 2017	69.99	29.3 %	0.78	-	69.99	0.78
Q3 2017	76.82	26.3 %	0.85	-	76.82	0.85
Q4 2017	63.12	22.1 %	0.70	(11.69)	74.81	0.83
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
Q1 2018	58.09	(31.7 %)	0.65	-	58.09	0.65
Q2 2018	18.73	(73.2 %)	0.21	-	18.73	0.21
Q3 2018	32.48	(57.7 %)	0.36	-	32.48	0.36
Q4 2018	32.47	(48.6 %)	0.36	-	32.47	0.36
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
Q1 2019	35.17	(39.5 %)	0.39	-	35.17	0.39
Q2 2019	15.35	(18.1 %)	0.17	-	15.35	0.17
Q3 2019	26.62	(18.1 %)	0.30	-	26.62	0.30
Q4 2019	69.79	115.0 %	0.78	13.39	56.41	0.63
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
Q1 2020	19.24	(45.3 %)	0.21	-	19.24	0.21
Q2 2020	6.99	(54.4 %)	0.08	-	6.99	0.08
Q3 2020	53.78	102.1 %	0.60	16.36	37.42	0.42
Q4 2020	51.98	(25.5 %)	0.58	34.87	17.11	0.19
2020	132.00	(10.2 %)	1.47	51.23	80.76	0.90
Q1 2021	52.61	173.4 %	0.58	-	52.61	0.58
Q2 2021	47.54	579.9 %	0.53	-	47.54	0.53
Q3 2021	49.85	(7.3 %)	0.55	-	49.85	0.55
Q4 2021	108.60	108.9 %	1.21	10.35	98.25	1.09
2021	258.60	95.9 %	2.87	10.35	248.26	2.76
Q1 2022	82.63	57.1 %	0.92	-	82.63	0.92
Q2 2022	69.52	46.2 %	0.77	-	69.52	0.77
Q3 2022	43.87	(12.0 %)	0.49	-	43.87	0.49

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2012	133.36	17.6 %	1.48	-	133.36	1.48
2013	136.63	2.5 %	1.52	-	136.63	1.52
2014	147.12	7.7 %	1.63	-	147.12	1.63
2015	165.06	12.2 %	1.83	13.75	151.31	1.68
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
2020	132.00	(10.2 %)	1.47	51.23	80.76	0.90
2021	258.60	95.9 %	2.87	10.35	248.26	2.76

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2013	44.79 %	24.18 %	20.16 %
Q2 2013	44.08 %	22.36 %	17.45 %
Q3 2013	43.63 %	21.80 %	16.56 %
Q4 2013	43.68 %	23.30 %	18.23 %
2013	43.68 %	23.16 %	18.23 %
Q1 2014	42.75 %	23.14 %	17.85 %
Q2 2014	42.69 %	22.94 %	18.48 %
Q3 2014	42.42 %	22.43 %	17.92 %
Q4 2014	41.90 %	22.11 %	17.11 %
2014	41.76 %	22.14 %	17.13 %
Q1 2015	41.98 %	21.38 %	15.76 %
Q2 2015	41.58 %	21.72 %	15.48 %
Q3 2015	41.54 %	21.77 %	15.49 %
Q4 2015	41.35 %	21.81 %	15.34 %
2015	41.32 %	22.03 %	15.35 %
Q1 2016	42.51 %	23.29 %	17.20 %
Q2 2016	43.49 %	24.24 %	18.50 %
Q3 2016	44.66 %	25.57 %	19.88 %
Q4 2016	46.07 %	24.94 %	19.47 %
2016	46.07 %	24.94 %	19.47 %
Q1 2017	46.32 %	26.38 %	21.29 %
Q2 2017	46.38 %	27.68 %	22.38 %
Q3 2017	46.73 %	29.19 %	24.08 %
Q4 2017	46.13 %	30.34 %	25.30 %
2017	46.13 %	30.34 %	25.30 %
Q1 2018	44.93 %	28.26 %	22.97 %
Q2 2018	42.33 %	24.50 %	18.99 %
Q3 2018	39.86 %	21.41 %	15.49 %
Q4 2018	36.95 %	18.60 %	12.00 %
2018	36.95 %	18.60 %	12.00 %
Q1 2019	35.60 %	17.66 %	9.96 %
Q2 2019	35.23 %	17.77 %	9.57 %
Q3 2019	35.16 %	17.58 %	8.93 %
Q4 2019	35.77 %	19.73 %	10.66 %
2019	35.77 %	19.73 %	10.66 %
Q1 2020	34.79 %	18.58 %	9.44 %
Q2 2020	33.85 %	18.13 %	9.05 %
Q3 2020	34.50 %	19.13 %	9.55 %
Q4 2020	34.12 %	16.71 %	6.13 %
2020	34.12 %	16.71 %	6.13 %
Q1 2021	34.76 %	18.09 %	7.62 %
Q2 2021	35.67 %	19.32 %	8.88 %
Q3 2021	35.20 %	18.83 %	8.64 %
Q4 2021	36.12 %	21.04 %	11.79 %
2021	36.12 %	21.04 %	11.79 %
Q1 2022	36.72 %	21.66 %	12.54 %
Q2 2022	37.15 %	22.13 %	12.98 %
Q3 2022	37.06 %	22.17 %	12.42 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2012	45.04 %	25.06 %	20.94 %
2013	43.68 %	23.16 %	18.23 %
2014	41.76 %	22.14 %	17.13 %
2015	41.32 %	22.03 %	15.35 %
2016	46.07 %	24.94 %	19.47 %
2017	46.13 %	30.34 %	25.30 %
2018	36.95 %	18.60 %	12.00 %
2019	35.77 %	19.73 %	10.66 %
2020	34.12 %	16.71 %	6.13 %
2021	36.12 %	21.04 %	11.79 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2013	45.94 %	25.32 %	21.25 %
Q2 2013	42.96 %	20.75 %	12.59 %
Q3 2013	39.90 %	18.63 %	13.07 %
Q4 2013	45.35 %	27.52 %	24.69 %
Q1 2014	42.20 %	24.47 %	19.51 %
Q2 2014	42.73 %	20.38 %	15.64 %
Q3 2014	39.09 %	16.97 %	11.38 %
Q4 2014	43.13 %	25.78 %	20.97 %
Q1 2015	42.48 %	21.43 %	14.17 %
Q2 2015	41.14 %	21.75 %	14.62 %
Q3 2015	39.26 %	17.88 %	11.96 %
Q4 2015	42.25 %	25.38 %	19.75 %
Q1 2016	46.50 %	26.86 %	21.08 %
Q2 2016	45.01 %	25.49 %	19.84 %
Q3 2016	44.80 %	24.50 %	18.81 %
Q4 2016	47.75 %	23.08 %	18.25 %
Q1 2017	47.43 %	32.36 %	28.09 %
Q2 2017	45.27 %	30.84 %	24.28 %
Q3 2017	46.32 %	30.89 %	26.02 %
Q4 2017	45.49 %	27.52 %	22.96 %
Q1 2018	42.69 %	24.11 %	18.82 %
Q2 2018	33.82 %	14.42 %	6.86 %
Q3 2018	36.08 %	18.15 %	11.56 %
Q4 2018	34.83 %	17.24 %	10.20 %
Q1 2019	37.45 %	20.42 %	10.95 %
Q2 2019	32.33 %	15.01 %	5.37 %
Q3 2019	35.77 %	17.35 %	8.83 %
Q4 2019	37.06 %	25.11 %	16.42 %
Q1 2020	33.62 %	15.88 %	6.12 %
Q2 2020	27.38 %	12.22 %	2.82 %
Q3 2020	37.81 %	21.04 %	10.67 %
Q4 2020	35.42 %	16.33 %	4.22 %
Q1 2021	35.75 %	20.37 %	10.64 %
Q2 2021	34.26 %	19.51 %	9.69 %
Q3 2021	35.37 %	18.67 %	9.16 %
Q4 2021	38.73 %	25.18 %	17.07 %
Q1 2022	38.02 %	22.74 %	13.56 %
Q2 2022	36.34 %	21.69 %	11.91 %
Q3 2022	35.19 %	19.15 %	7.30 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2013	90.00	1.49	1.49	12.83
Q2 2013	90.00	1.34	1.34	12.37
Q3 2013	90.00	1.32	1.32	12.64
Q4 2013	90.00	1.52	1.52	13.22
Q1 2014	90.00	1.53	1.53	13.75
Q2 2014	90.00	1.65	1.65	13.36
Q3 2014	90.00	1.65	1.65	13.65
Q4 2014	90.00	1.63	1.63	14.15
Q1 2015	90.00	1.72	1.56	14.74
Q2 2015	90.00	1.73	1.58	14.63
Q3 2015	90.00	1.79	1.63	14.86
Q4 2015	90.00	1.83	1.68	15.48
Q1 2016	90.00	1.95	1.97	16.15
Q2 2016	90.00	2.15	2.21	15.76
Q3 2016	90.00	2.53	2.48	16.26
Q4 2016	90.00	2.50	2.52	16.85
Q1 2017	90.00	2.80	2.79	17.78
Q2 2017	90.00	2.97	2.93	17.24
Q3 2017	90.00	3.15	3.22	18.05
Q4 2017	90.00	3.28	3.41	18.80
Q1 2018	90.00	2.98	3.11	19.41
Q2 2018	90.00	2.41	2.54	17.98
Q3 2018	90.00	1.92	2.05	18.34
Q4 2018	90.00	1.58	1.58	17.79
Q1 2019	90.00	1.32	1.32	18.07
Q2 2019	90.00	1.28	1.28	16.24
Q3 2019	90.00	1.22	1.22	16.54
Q4 2019	90.00	1.63	1.48	16.91
Q1 2020	90.00	1.46	1.31	16.57
Q2 2020	90.00	1.36	1.21	16.65
Q3 2020	90.00	1.66	1.33	17.25
Q4 2020	90.00	1.47	0.90	19.94
Q1 2021	90.00	1.84	1.27	19.89
Q2 2021	90.00	2.29	1.72	20.42
Q3 2021	90.00	2.24	1.86	20.86
Q4 2021	90.00	2.87	2.76	20.74
Q1 2022	90.00	3.21	3.09	21.70
Q2 2022	90.00	3.45	3.34	22.47
Q3 2022	90.00	3.38	3.27	21.96

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2012	90.00	1.48	1.48	12.40
2013	90.00	1.52	1.52	13.22
2014	90.00	1.63	1.63	14.15
2015	90.00	1.83	1.68	15.48
2016	90.00	2.50	2.52	16.85
2017	90.00	3.28	3.41	18.80
2018	90.00	1.58	1.58	17.79
2019	90.00	1.63	1.48	16.91
2020	90.00	1.47	0.90	19.94
2021	90.00	2.87	2.76	20.74

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2013	23.15	23.15	2.70
Q2 2013	26.26	26.26	2.85
Q3 2013	26.93	26.93	2.82
Q4 2013	26.15	26.15	3.00
Q1 2014	33.02	33.02	3.69
Q2 2014	33.91	33.91	4.19
Q3 2014	43.67	43.67	5.29
Q4 2014	45.25	45.25	5.23
Q1 2015	40.15	44.08	4.67
Q2 2015	45.84	50.27	5.43
Q3 2015	32.29	35.31	3.88
Q4 2015	27.26	29.73	3.23
Q1 2016	27.46	27.14	3.31
Q2 2016	28.54	27.81	3.89
Q3 2016	21.29	21.71	3.31
Q4 2016	27.05	26.85	4.01
Q1 2017	25.95	25.99	4.08
Q2 2017	26.81	27.16	4.62
Q3 2017	24.63	24.12	4.30
Q4 2017	21.93	21.10	3.82
Q1 2018	24.80	23.77	3.80
Q2 2018	28.42	26.97	3.81
Q3 2018	22.92	21.46	2.39
Q4 2018	25.39	25.39	2.25
Q1 2019	32.81	32.81	2.40
Q2 2019	34.90	34.90	2.76
Q3 2019	36.10	36.10	2.66
Q4 2019	25.93	28.53	2.50
Q1 2020	28.43	31.66	2.50
Q2 2020	31.13	34.94	2.55
Q3 2020	30.78	38.40	2.97
Q4 2020	35.71	58.36	2.63
Q1 2021	31.13	45.10	2.88
Q2 2021	37.67	50.14	4.22
Q3 2021	34.24	41.38	3.68
Q4 2021	28.37	29.55	3.93
Q1 2022	34.32	35.59	5.07
Q2 2022	34.85	36.05	5.35
Q3 2022	50.66	52.45	7.81

Period	P/E	Adjusted P/E	Price/book
2012	25.26	25.26	3.02
2013	26.15	26.15	3.00
2014	45.25	45.25	5.23
2015	27.26	29.73	3.23
2016	27.05	26.85	4.01
2017	21.93	21.10	3.82
2018	25.39	25.39	2.25
2019	25.93	28.53	2.50
2020	35.71	58.36	2.63
2021	28.37	29.55	3.93

Business Segments (Million)

Compared With The

Period	Medical Services	Medicine and Pharmaceutical Products
Q1 2013	169.97	13.76
Q2 2013	168.24	19.56
Q3 2013	158.17	8.92
Q4 2013	192.80	18.25
Q1 2014	195.44	12.12
Q2 2014	201.76	17.69
Q3 2014	177.26	15.52
Q4 2014	223.36	16.72
Q1 2015	224.02	16.38
Q2 2015	228.38	16.85
Q3 2015	215.41	8.52
Q4 2015	257.40	18.49
Q1 2016	276.15	8.88
Q2 2016	277.42	10.93
Q3 2016	265.04	8.13
Q4 2016	307.51	8.73
Q1 2017	239.94	62.81
Q2 2017	229.31	58.90
Q3 2017	235.08	60.17
Q4 2017	241.44	84.43
Q1 2018	236.76	71.84
Q2 2018	205.73	67.39
Q3 2018	218.43	62.50
Q4 2018	228.74	89.55
Q1 2019	239.22	81.93
Q2 2019	210.95	75.06
Q3 2019	232.55	68.79
Q4 2019	259.40	84.20
Q1 2020	227.83	86.77
Q2 2020	166.96	80.60
Q3 2020	260.50	90.30
Q4 2020	309.74	95.55
Q1 2021	378.70	115.97
Q2 2021	374.54	116.29
Q3 2021	412.23	131.88
Q4 2021	472.23	103.34
Q1 2022	470.53	138.87
Q2 2022	475.30	108.52
Q3 2022	438.86	162.03

Period	Medical Services	Medicine and Pharmaceutical Products
2012	587.00	49.85
2013	689.17	60.48
2014	797.83	62.05
2015	925.20	60.24
2016	1,126.12	36.67
2017	945.78	266.30
2018	889.66	291.28
2019	942.12	309.97
2020	965.03	353.22
2021	1,637.71	467.47

Analysts Estimates (Million)

Item	Q3 2022 (e)	Q3 2022 (a)	Change‬
Average	78.24	43.87	(43.9 %)

Estimates vs Actual (Million)

Item	Q3 2022 (e)	Q3 2022 (a)	Change
Al Rajhi Capital	76.00	43.87	(42.3) %
AlJazira Capital	78.80	43.87	(44.3) %
OSOOL AND BAKHEET	79.91	43.87	(45.1) %

Financial Ratios

	Current
Market Cap (M Riyal)	14,945.04
Enterprise Value (EV) (M)	16,864.64
Shares Outstanding ((M))	97.68
EPS ( Riyal) (TTM)	4.82
Book Value (BV) ( Riyal)	34.96
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	31.73
P/E (TTM)	31.73
Price/book	4.38
Return on Average Assets (%) (TTM)	7.5
Return on Average Equity (%) (TTM)	14.3

Dallah Healthcare Co. (DALLAH HEALTH)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Dallah Healthcare 9M 2022 net profit leaps 31% to SAR 196 mln; Q3 at SAR 43.9 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2022 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Dallah Healthcare 9M 2022 net profit leaps 31% to SAR 196 mln; Q3 at SAR 43.9 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q3 2022

Revenue by Business Segment (Latest) 2022 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)